Compliance With Fluoxetine Use in Men With Primary Premature Ejaculation
| Autor: | Marilyn Parker, Raanan Tal, Joshua Gonzalez, Lawrence C. Jenkins, Patricia Guhring, John P. Mulhall |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Ejaculation Urology Endocrinology Diabetes and Metabolism Population 030232 urology & nephrology Article 03 medical and health sciences 0302 clinical medicine Endocrinology Internal medicine Fluoxetine Premature ejaculation medicine Humans Premature Ejaculation education Depression (differential diagnoses) education.field_of_study 030219 obstetrics & reproductive medicine business.industry Middle Aged Psychiatry and Mental health Distress Sexual dysfunction Treatment Outcome Reproductive Medicine Population study Patient Compliance medicine.symptom business Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | J Sex Med |
| ISSN: | 1743-6109 |
| Popis: | Background Premature ejaculation (PE) is a common sexual dysfunction for which selective serotonin reuptake inhibitors (SSRIs) have been used effectively for treatment. However, compliance with therapy and predictors of long-term SSRI use in the treatment of PE are not well known. Aim To analyze our experience with drop-out rates with fluoxetine in the primary PE population and to identify predictors of continued use of this agent. Methods Men with primary PE constituted who used fluoxetine and had at least 12 months follow-up constituted the study population. Subjects underwent a comprehensive interview to ascertain self-reported (non-stopwatch) intravaginal ejaculatory latency time (IELT), self-rated control over ejaculation, and personal and patient-reported partner distress due to PE. Patients were treated with fluoxetine 20 mg daily, with the possibility of dose titration up or down based on efficacy and side effects. Outcomes The PE parameters of interest included self-reported IELT, self-rated control over ejaculation, personal and partner distress due to PE, and medication adherence. Results 130 men were included in the study. Dropout rates at 6 and 12 months were 56% and 72%. Self-rated “poor” ejaculatory control decreased from 98%–41% (P < .01), high personal distress from 47%–11% (P Clinical Implications Compliance with SSRIs is a well-described problem in the depression literature, but data are sparse regarding continued use of SSRIs in the treatment of PE. Strengths and Limitations We report on 12-month compliance with SSRIs for the treatment of PE. Our early compliance rates were more encouraging than what has been reported in the past. However, IELT was self-reported and not measured objectively, and we did not use validated patient-reported outcomes but rather self-reported ejaculatory control and distress levels, which have limitations. Conclusions Fluoxetine is an effective agent for the treatment of PE with significant improvement realized in IELT, ejaculatory control, and distress levels for both men and their partners. Despite its efficacy, continued use of fluoxetine beyond 6 months is poor. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|